ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.

Management Team

Jaume Pons, PhD

President and Chief Executive Officer

Sophia Randolph, MD, PhD

Chief Medical Officer

Jeanne Jew

Chief Business Officer

Peter García

Chief Financial Officer

Steffen Pietzke

Vice President, Finance and Chief Accounting Officer

Michael Chang, PhD

Vice President, Operations

Hank Stern

Vice President, Chemistry, Manufacturing and Controls

Michael Warner, JD, PhD

Acting General Counsel